Table 2.

Lifetime Cost-Effectiveness Results for Base Case and Sensitivity Analyses

	SST+tPA Costs ($)	tPA Costs ($)	Δ Costs ($) (95% CI)	SST+tPA QALYs	tPA QALYs	Δ QALYs (95% CI)*	ICER ($ per QALY)	% Dominant	% Dominated	% <$50K
Base case	215 781	238 984	−23 203 (−56 946 to 12 933)	6.789	5.046	1.743 (0.760–2.786)	Dominant	90.0	0.0	100
Benefit in life-years	215 781	238 984	−23 203 (−56 946 to 12 933)	9.128	7.920	1.208* (0.287–2.168)	Dominant	89.5	0.1	99.9
Sensitivity analyses
Historical costs	135 876	127 368	8507 (−6565 to 23 804)	6.789	5.046	1.743 (0.760–2.786)	4881	13.8	0.0	99.9
No nursing home costs	152 861	129 371	23 490 (12 960 to 34 573)	6.789	5.046	1.743 (0.760–2.786)	12 631	0.0	0.0	99.9
No long-term costs	57 030	44 752	12 278 (5786 to 19 080)	6.789	5.046	1.743 (0.760–2.786)	7044	0.0	0.0	99.8
Benefit in DALYs	215 781	238 984	−23 203 (−56 946 to 12 933)	7.235	5.156	2.079 (0.933–3.253)	Dominant	90.0	0.0	100
Calibration factor 1	259 157	298 738	−39 581 (−84 455 to 8897)	8.396	6.306	2.089 (0.904–3.341)	Dominant	95.0	0.0	100
Calibration factor 3	180 912	192 682	−11 770 (−38 382 to 16 280)	5.448	4.013	1.436 (0.622–2.273)	Dominant	80.6	0.0	100
Calibration factor 5	149 596	152 580	−2 984 (−23 325 to 18 445)	4.200	3.066	1.134 (0.486–1.781)	Dominant	60.4	0.0	99.8

CI indicates confidence interval; DALY, disability-adjusted life-years; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-years; SST, Solitaire stent thrombectomy; and tPA, tissue-type plasminogen activator.

^*Results in QALYs unless otherwise specified as life-years or DALYs.